We Claim:

1. A film-coated tablet containing talsaclidine comprising:

(a) a core comprising talsaclidine or a physiologically acceptable acid addition salt thereof; and

(b) a film coating,

wherein the film coating envelops the core.

2. The tablet according to claim 1, wherein the core further comprises a modified lactose excipient.

3. The tablet according to claim 2, wherein the modified lactose excipient is spray-dried lactose.

4. The tablet according to claim 1, wherein the talsaclidine is in the form of an acid addition salt selected from the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, and maleic acid.

5. The tablet according to claim 1, wherein the talsaclidine in the core is present in an amount of from 0.5 wt.% to 25 wt.% of the total mass of the core.

6. The tablet according to claim 1, wherein the talsaclidine in the core is present in an amount of from 0.7 wt.% to 20 wt.% of the total mass of the core.

7. The tablet according to claim 2, wherein the weight ratio between the modified lactose excipient to talsaclidine is in a range from about 1:1 to about 70:1.

8. The tablet according to claim 2, wherein the weight ratio between the modified lactose excipient to talsaclidine is in a range from about 1.5:1 to about 35:1.

9. The tablet according to claim 2, wherein the core further comprises a dry binder.

10. The tablet according to claim 9, wherein the weight ratio of the modified lactose excipient to dry binder is in the range from about 5:1 to about 1:4.

11. The tablet according to claim 10, wherein the weight ratio of the modified lactose excipient to dry binder is in the range from about 4:1 to about 1:3.

12. The tablet according to claim 2, wherein the core further comprises a disintegrant.

13. The tablet according to claim 12, wherein the disintegrant in the core is present in an amount of from about 1 wt.% to about 10 wt.% of the total mass of the core.

14. The tablet according to claim 1, wherein the core further comprises a flow regulator.

15. The tablet according to claim 14, wherein the flow regulator in the core is present in an amount of from about 0.1 wt.% to about 5 wt.% of the total mass of the core.

16. The tablet according to claim 1, wherein the core further comprises a flow agent, lubricant, or mould release agent.

17. The tablet according to claim 16, wherein the flow agent, lubricant, and mould release agent in the core are present in an amount of from about 0.1 wt.% to about 5 wt.% of the total mass of the core.

18. The tablet according to claim 1, wherein the film coating comprises a film-forming agent selected from the group consisting of: hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, and poly(ethylacrylate) methylmethacrylate.

19. The tablet according to claim 1, wherein the film coating comprises a film-forming agent selected from the group consisting of: EUDRAGIT® NE 30 D, EUDRAGIT® RL 30 D, and EUDRAGIT® E.

20. The tablet according to claim 18, wherein the film-forming agents in the film coating are present in an amount of from about 20 wt.% to about 95 wt.% of the total mass of the film coating.

21. The tablet according to claim 18, wherein the film coating further comprises an emulsifier or a plasticizer.

22. The tablet according to claim 18, wherein the film coating further comprises a plasticizer.

23. The tablet according to claim 22, wherein the plasticizers in the film coating are present in an amount of from about 1 wt.% to about 30 wt.% of the total mass of the film coating.